SHC Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -5.45%, SMA50 -7.88%, SMA200 7.9%). The stock’s 14-day RSI is 34.62 (weak momentum), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.03% below its high and over 72.82% above its low. Average 10-day trading volume of 2.51 million shares is in line with the 3-month average of 2.39 million, indicating normal recent market interest.

Wall Street analysts project EPS growth of 10.84% annually over the next five years. The latest quarter delivered EPS of $0.17. The next quarter is forecast at $0.18. Next year's EPS is expected at $8.80. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 1 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $13.00. The high target offers 50.66% upside. The low target suggests -18.39% downside. The mean target is $19.30. This offers 21.16% upside. Sotera Health Company earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by -23.27%. The prior quarter beat by 17.65%. Over the last six quarters, Apple has recorded several small beats. These include 11.76% in August 05, 2024.

Sotera Health Company has 284.05 million shares outstanding. The public float is 133.90 million shares, elevated short interest at 9.16% of float. This equals 14.13 million shares. The short ratio is 14.05 days. Institutional investors hold 80.0% of the float. Insiders own 2.34%. WARBURG PINCUS & CO. holds 19.10 million shares, GTCR INVESTMENT XI LLC has 12.74 million shares and Rutz Michael P has 450.20 thousand shares. Over the past six months, insider transactions show net selling. They sold 71.24 million shares across 7 transactions.

Sotera Health Company (NASDAQ:SHC) closed at $15.83 USD, losing -$0.20 (-1.27%) from the previous close of $16.03. The stock is currently mid-range between its 52-week high and low $10.17 and $19.85. With a market capitalization of about $4.50 billion, Sotera Health Company is classified as a mid-cap and shows higher-than-market volatility (beta ~1.88). Key stats such as the average daily volume over the past year has been around 2.89 million shares, volume is running light vs its 52-week average. Headquartered in Broadview Heights, OH, Sotera Health Company operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Michael Petras Jr., the company employs approximately 3,000 people and listed since November 20, 2020. Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally.

Sotera Health Company last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.43. This means the shares are trading below this model’s fair value.

Sotera Health Company trades at a P/E ratio of 57.85, slightly above the S&P 500 average, with a price-to-sales ratio of 3.88 and a price-to-book ratio of 7.44 trading at moderately above to book value. The P/FCF stands at 30.7, also below market averages.

Sotera Health Company (NASDAQ:SHC) shares are flat 5.95% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Sotera Health Company trading at a premium to the broader market with a P/E of 57.85. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $18.17, suggesting 14.06% upside. Our AI forecast model points to short-term strength (7.85% over two weeks), a medium-term rise (35.15% over three months), and a longer-term gain (10.99% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Sotera Health Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.85%, with price expected at $17.18 by April 28, 2026, within a range of $16.65 to $17.73 3-Month Outlook: Projected rise of 35.15%, reaching $21.53 by July 13, 2026, with a range of $21.01 to $22.18. 1-Year Outlook: Projected gain of 10.99%, with price at $17.68 by April 14, 2027, within a range of $16.71 to $18.47.